Which inherited bleeding disorder, specifically von Willebrand disease (type 1), is associated with recurrent postpartum hemorrhage in successive pregnancies?

Von Willebrand Disease Type 1

Recurrent postpartum hemorrhage across successive pregnancies should prompt immediate evaluation for von Willebrand disease (VWD), particularly type 1, which is the most common inherited bleeding disorder and accounts for 75% of all VWD cases 1.

Clinical Presentation and Risk

VWD is characterized by deficiency or dysfunction of von Willebrand factor (VWF), manifesting as excessive mucocutaneous bleeding including:

• Heavy menstrual bleeding
• Easy bruising
• Prolonged bleeding from minor wounds
• Postpartum hemorrhage (both primary and secondary) 1

Women are disproportionately affected and more likely to be diagnosed due to menstruation and childbirth challenges 1.

Postpartum Hemorrhage Patterns in VWD

Primary PPH (≤24 hours postpartum)

The risk of primary PPH in women with known type 1 VWD is approximately 2.8-10% 2, 3, which is comparable to or slightly higher than the general population (3-8%). Notably, VWD type 3 carries significantly higher risk of severe primary PPH compared to other subtypes 4.

Secondary PPH (24 hours to 12 weeks postpartum)

This is where VWD becomes particularly concerning: secondary PPH occurs in approximately 12-15% of pregnancies with type 1 VWD 2, compared to only 1% in the general obstetric population. Secondary PPH typically occurs 2-19 days postpartum 2.

Diagnostic Criteria

The 2021 evidence-based guidelines establish three diagnostic criteria for VWD 1, 5:

1. Personal history of excessive mucocutaneous bleeding
2. Family history of bleeding
3. Reduced VWF levels

Laboratory Findings for Type 1 VWD

• VWF antigen (VWF:Ag): Decreased to markedly decreased
• VWF activity: Decreased to markedly decreased
• VWF activity/Ag ratio: >0.7
• Factor VIII: Normal to decreased
• Multimers: Normal 1

Critical Clinical Pitfall

The most dangerous scenario is when VWD diagnosis is unknown at time of delivery—this significantly increases the risk of secondary PPH 4. Women with undiagnosed VWD face preventable morbidity and mortality.

Why Recurrent PPH Points to VWD

During pregnancy, VWF levels physiologically increase, which can temporarily normalize laboratory values and mask the diagnosis 6, 7, 8. However, after delivery, VWF levels drop rapidly, unmasking the underlying deficiency and leading to delayed hemorrhage 6, 8. This explains the pattern of recurrent PPH across multiple pregnancies.

Factor VIII levels in pregnancy are inversely correlated with blood loss during delivery 4, making third-trimester monitoring essential.

Prevalence Context

VWD affects up to 1% of the general population, with symptomatic prevalence of approximately 1 in 1,000 (0.1%) 1. Type 1 VWD represents 75% of all VWD cases 2, making it the most likely diagnosis in women with recurrent PPH.

Additional Inherited Bleeding Disorders

While VWD type 1 is the most common cause, other inherited hemostatic disorders can present with recurrent PPH 9. In one study of women with severe PPH, 55.6% received a specific diagnosis of an inherited bleeding disorder, with VWD being the most frequent 9.

Management Implications

Early identification before pregnancy is critical to prevent and effectively treat PPH 9, 6, 8. Treatment options include:

• Desmopressin (DDAVP)
• VWF concentrates (plasma-derived or recombinant)
• Tranexamic acid
• Hormonal therapy 6, 10

Multidisciplinary peripartum planning with careful monitoring of VWF activity levels in the third trimester is essential 6, 8, 3.